CHICAGO & IRVINE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) and Masimo (Nasdaq: MASI) today announced a joint agreement to integrate Masimo Signal Extraction Technology® (SET®) pulse ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of the rainbow ® Super DCI ®-mini sensor, a reusable spot-check sensor that features Masimo SET ® ...
GE Healthcare and Masimo have announced a joint agreement to integrate Masimo’s Signal Extraction Technology (SET) pulse oximetry into GE’s Portrait Mobile wireless and wearable patient monitoring ...
Masimo Corp. ((MASI)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Medical Device Network on MSN
Masimo secures FDA approval for OIRD detection on wearable patient monitor
The newly cleared capability uses AI through the smartSET pulse oximetry sensor platform.
Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring ...
Masimo MASI recently unveiled its newest health-tracking wearable, the Masimo Freedom smartwatch. The product uses the Masimo SET pulse oximetry to accurately capture health data on the wrist. The ...
The Portrait Mobile system’s around-the-clock readings are meant to be an upgrade to traditional in-hospital monitoring methods, which typically check on patients’ vital signs only once every few ...
The FDA clearance allows the W1 wearable to be sold for both over-the-counter and prescription use—making it the first SpO2-tracking smartwatch to carry both indications in the U.S., per Masimo.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results